Cassady Schiller Wealth Management’s Vaxcyte PCVX Stock Holding History

Cassady Schiller Wealth Management’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$573	Buy	+7	New	+$695	﹤0.01%	934

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Cassady Schiller Wealth Management's PCVX Position: Q4 2024 in Review

Cassady Schiller Wealth Management opened a new position in Vaxcyte (PCVX) in Q4 2024: 7 shares worth $573. The stake represents ﹤0.01% of the portfolio and ranks #934 among its holdings.

323 funds tracked by Wall St. Rank hold PCVX as of Q4 2024.

Cassady Schiller Wealth Management held 7 shares of Vaxcyte worth $573 as of Q4 2024.
Vaxcyte was a new Cassady Schiller Wealth Management position in Q4 2024.
Vaxcyte made up ﹤0.01% of Cassady Schiller Wealth Management's portfolio in Q4 2024, its #934 holding.
323 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2024.

Based on Cassady Schiller Wealth Management's 13F filing for Q4 2024, filed 10 Feb 2025.